Corneal Ulcer Clinical Trial
Official title:
The Asia Cornea Society Infectious Keratitis Study
Corneal diseases are a major cause of blindness worldwide, and corneal infections are a
substantial cause of blindness in Asia. The aim of the Asia Cornea Society Infectious
Keratitis Study (ACSIKS) is to study infectious keratitis (corneal infections) in Asian
countries, so as to improve strategies for prevention and treatment, and to reduce the
burden of blindness in Asia.
The first phase of ACSIKS is an 18-month observational study involving 11 eye hospitals in 8
Asian countries; these hospitals manage more than 6700 cases of corneal infections every
year. From the first quarter of 2012, all patients with a corneal infection will be
recruited and a standard ACSIKS protocol will be applied; this protocol includes the use of
a common set of study forms and a suggested panel of microbiological examinations. However,
each centre will be continue to treat their patients with the anti-infective therapy
standard for their centre. Data will be recorded for each patient for a period of six
months, including their medical and surgical management, the final clinical outcome and
vision.
Bacterial and fungal growths from patients will also be stored for further research during a
second phase of ACSIKS. These studies will focus on evaluating the resistance of the most
common bacterial infections to the current available antibiotics, performing DNA testing to
compare our strains with bacterial infections in the West, and to developing new diagnostic
tests and anti-infective therapies tailored to corneal infections in Asia.
Summary of the ACSIKS Clinical Protocol:
All patients with an initial clinical diagnosis of infectious keratitis will be referred by
the attending ophthalmologist-in-charge to an ACSIKS co-investigator or trial coordinator
for recruitment into the study. Patients will be enrolled in the study after study informed
consent is obtained and a trained interviewer will administer a standardized ACSIKS Clinical
Case Report Form to each recruited subject. Information that will be documented would
include the demographic profile (e.g. age, gender, ethnic group, occupation, etc), risk
factors for infectious keratitis, presenting symptoms and prior treatment.
Patients who are contact lens wearers will also complete a separate contact lens
questionnaire, with specific questions on duration of contact lens wear, type of contact
lens and solutions used, lens wear schedule and habits, and adherence to lens care
practices.
All patients will undergo a thorough ocular examination by the ophthalmologist-in-charge or
an ACSIKS co-investigator, and details of the infectious keratitis and associated findings
documented on the ACSIKS Clinical CRF. With the approval of the ophthalmologist-in-charge,
corneal scrapings will then be collected as per the ACSIKS Microbiological Protocol. Each
study subject will consequently still be managed by the ophthalmologist-in-charge according
to his/her current clinical approach, with appropriate medical or surgical treatment carried
out in accordance with the practice patterns and standards of his/her institution, and no
attempt to deviate from current treatment practices.
Regular chart reviews will be performed by ACSIKS trial coordinators for the six months
duration of the subjects' involvement to document the initial differential diagnoses and
medical treatment, the microbiological results, and any changes to the diagnosis and
treatment. The last consultation with the ophthalmologist-in-charge during that six
month-period will be taken as the final study review.
Summary of the ACSIKS Microbiological Protocol:
At the discretion of the ophthalmologist-in-charge, corneal scrapings will be collected
based on a list of investigations suggested by the ACSIKS Group.
All microbiological specimens will be incubated, interpreted and reported according to
agreed upon common standards, regardless of the number of colonies present. Bacterial
organisms will also be tested using standardized antibiograms agreed upon by microbiologists
from the various participating institutions. Results of any and all microbiological testing
will be collected and recorded into the ACSIKS Microbiological Case Report Form.
If these samples do yield a positive growth of either fungal or bacterial organisms (or
both), the causative organisms cultured will be sub-cultured and stored at each site's
ACSIKS freezer, for subsequent transport to the ACSIKS Central Repository in Singapore for
use in future microbial studies under Phase 2 of the ACSIKS project.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05705024 -
Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells
|
Phase 2 | |
Completed |
NCT02731638 -
Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
|
Phase 3 | |
Completed |
NCT00324168 -
Steroids for Corneal Ulcers Trial
|
Phase 4 | |
Completed |
NCT04484402 -
Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells
|
Phase 1/Phase 2 | |
Completed |
NCT04820010 -
Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
|
||
Recruiting |
NCT02570321 -
Cross-linking for Corneal Ulcers Treatment Trial
|
Phase 4 | |
Completed |
NCT00386958 -
A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers
|
Phase 2 | |
Completed |
NCT04054817 -
ACRO Biocornea Clinical Trial in Taiwan
|
N/A | |
Completed |
NCT00997035 -
The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo
|
Phase 3 | |
Completed |
NCT02277054 -
Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty
|
N/A | |
Recruiting |
NCT05313828 -
Effect of Various Treatment Modalities on Dendritic Vial Ulcer
|
||
Recruiting |
NCT05255016 -
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers
|
Phase 2/Phase 3 | |
Recruiting |
NCT05255107 -
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers
|
Phase 2/Phase 3 | |
Completed |
NCT05891106 -
AONDA Therapeutic Indication Study I
|
||
Terminated |
NCT00789646 -
Painless Subconjunctival Antibiotic and Antifungal Injection in Corneal Ulcer Patients
|
N/A | |
Not yet recruiting |
NCT05940376 -
Topical Insulin in Neurotrophic Keratopathy After Diabetic Vitrectomy
|
||
Completed |
NCT05200000 -
Wharton's Jelly Eye Drops in the Treatment of Chronic Keratitis
|
Phase 1 | |
Completed |
NCT01756456 -
Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01969786 -
Village Integrated Eye Workers Trial
|
N/A | |
Completed |
NCT01794312 -
Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
|
Phase 3 |